Etoposide

Title	Average Rating
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.	90.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.	80.00%
Different metronomic treatment schedules	80.00%
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.	80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients ....	80.00%
Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of local..	80.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer.....	75.00%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r	70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma	70.00%
Clinical management of adrenocortical carcinoma	60.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer	50.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non.....	40.00%

Languages